In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...

The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

02 July 2025 Zoom Draft Agenda The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to change ...

01 July 2025 via Zoom Draft Agenda The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to ...

Our updated guideline reflects this change in practice and in doing so they recommend an earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozinthan we’ve recommended before. It means they ...

Home NICE Guidance Conditions and diseases Blood and immune system conditions Blood and bone marrow cancers Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there is ...

Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. Last reviewed: 24 June 2025 Next review: ...

Marstacimab (Hympavzi, Pfizer) is indicated for 'routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: severe haemophilia A (congenital factor ...